Zenith is attending AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Nov 5-9 2015 in Boston. Yet to be disclosed by Zenith or on the conference website whether they are presenting.

Resverlogix is attending and presenting at the 2015 American Heart Association Scientific Sessions, Nov 7-11 2015 in Orlando, FL. Norman Wong is listed as first author for "S 1006 - RVX-208 a Selective Bromodomain and Extra-terminal BET Protein Inhibitor Acts on Several Pathways to Benefit Cardiovascular Risks" on November 8, part of the session "APS.01.01 - New Insights into Treatment of Cardiovascular Disease." Looks like Dr. Henry Ginsberg, who is on the BETonMACE clinical steering committee, is chairing this session.

In the AGM transcript that Masila posted, it reads "More presentations coming - wait until you see what comes out over the next few months, not just cardiovascular. We have a major presentation in SanDiego at the International Nephrology conference related to MACE data being presented by Dr. Kalantar." My best guess is that this is the American Society for Nephrology Kidney Week conference, Nov 3-8, 2015 in San Diego, CA. Dr. Kalantar is listed as giving a few talks at this conference, though it's not clear if any of these are RVX-208/MACE related.

So looks like from the science standpoint, we've got good potential for new information/data for cancer (Zenith/AACR conference), cardiovascular (Resverlogix, RVX-208/AHA conference) and kidney/MACE (Resverlogix, RVX-208/Kidney week conference) in the next 4 weeks.

BearDownAZ